Today, Boston Advisors LLC Sold shares of United Therapeutics Corp. (UTHR)

Today, Boston Advisors LLC Sold shares of United Therapeutics Corp. (UTHR)

Boston Advisors LLC lowered its position in United Therapeutics Corp. (NASDAQ:UTHR) by 24.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,695 shares of the biotechnology company’s stock after selling 1,210 shares during the period. Boston Advisors LLC’s holdings in United Therapeutics Corp. were worth $391,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in UTHR. Daiwa Securities Group Inc. increased its position in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 150 shares during the last quarter. Nordea Investment Management AB increased its position in United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 190 shares during the last quarter. Eqis Capital Management Inc. purchased a new position in United Therapeutics Corp. during the second quarter valued at approximately $254,000. Creative Planning increased its position in United Therapeutics Corp. by 330.4% in the second quarter. Creative Planning now owns 2,410 shares of the biotechnology company’s stock valued at $255,000 after buying an additional 1,850 shares during the last quarter. Finally, Acrospire Investment Management LLC purchased a new position in United Therapeutics Corp. during the first quarter valued at approximately $267,000.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) traded down 0.20% on Thursday, hitting $121.22. The stock had a trading volume of 396,791 shares. United Therapeutics Corp. has a 1-year low of $97.52 and a 1-year high of $164.04. The company has a market capitalization of $5.27 billion, a PE ratio of 5.86 and a beta of 1.42. The firm has a 50-day moving average of $122.83 and a 200 day moving average of $115.91.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings data on Thursday, July 28th. The biotechnology company reported $4.55 EPS for the quarter, beating the consensus estimate of $3.22 by $1.33. The firm earned $412.60 million during the quarter, compared to the consensus estimate of $395.15 million. United Therapeutics Corp. had a net margin of 64.26% and a return on equity of 49.30%. The company’s quarterly revenue was up 18.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.55 earnings per share. On average, equities analysts anticipate that United Therapeutics Corp. will post $15.82 earnings per share for the current fiscal year.

UTHR has been the topic of several research reports. Argus reaffirmed a “hold” rating on shares of United Therapeutics Corp. in a research report on Tuesday, August 23rd. Zacks Investment Research raised United Therapeutics Corp. from a “hold” rating to a “buy” rating and set a $126.00 price target on the stock in a research report on Tuesday, July 26th. Cowen and Company reissued a “buy” rating and set a $144.00 price target on shares of United Therapeutics Corp. in a research report on Friday, September 23rd. Wedbush reissued an “outperform” rating and set a $229.00 price target on shares of United Therapeutics Corp. in a research report on Thursday, July 28th. Finally, Jefferies Group reissued a “hold” rating and set a $120.00 price target on shares of United Therapeutics Corp. in a research report on Friday, July 29th. Eight research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $137.09.

In related news, CEO Martine A. Rothblatt sold 1,292 shares of the business’s stock in a transaction dated Thursday, July 14th. The shares were sold at an average price of $110.05, for a total transaction of $142,184.60. Following the transaction, the chief executive officer now owns 1,432 shares in the company, valued at $157,591.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Martine A. Rothblatt sold 1,284 shares of the business’s stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $112.77, for a total transaction of $144,796.68. Following the transaction, the chief executive officer now owns 1,424 shares in the company, valued at approximately $160,584.48. The disclosure for this sale can be found here. Insiders own 7.50% of the company’s stock.

United Therapeutics Corp. Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

Related posts

Leave a Comment